Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 8, 2004, Pages 841-843

  Huo, Teh Ia ^a   Wu, Jaw Ching ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN M; LAMIVUDINE;

DISEASE EXACERBATION; EDITORIAL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER DISEASE; PRIORITY JOURNAL; REINFECTION; VIRUS ACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 4143094696     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03525.x     Document Type: Editorial

References (27)

1. Lee W. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733-45.
2. Wang YJ, Lee SD, Wu JC et al. Acute hepatitis B viral infection in a patient with anti-HBs. J. Med. Virol. 1991; 35: 133-5.
3. Huo TI, Wu JC, Yen FS et al. Polymerase chain reaction analysis for viral nucleic acids in acute sporadic hepatitis patients negative for serum hepatitis B surface antigen and antibodies to hepatitis C virus. J. Chin. Med. Assoc. 1996; 58: 379-84.
4. Yuki N, Nagaoka T, Yamashiro M et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37: 1172-9.
5. McMahon BJ, Alberts SR, Wainwright RB et al. Hepatitis B-related sequelae: prospective study in 1,400 hepatitis B surface antigen-positive Alaska native carriers. Arch. Intern. Med. 1990; 150: 1051-4.
6. Huo TI, Wu JC, Lee PC et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28: 231-6.
7. Degos F, Lugassy C, Degott C et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients: a prospective study of 90 patients. Gastroenterology 1988; 94: 151-6.
8. Fairley CK, Mijch A, Gust ID et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 1991; 52: 497-500.
9. Huo TI, Yang WC, Wu JC et al. Kidney transplantation in patients with chronic hepatitis B virus infection: is the prognosis worse? Dig. Dis. Sci. 2001; 46: 469-75.
10. Harnett JD, Zeldis JB, Parfrey PS et al. Hepatitis B disease in dialysis and transplant patients: further epidemiologic and serologic studies. Transplantation 1987; 44: 369-76.
11. Lee WC, Wu MJ, Cheng CH et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am. J. Kidney Dis. 2001; 38: 1074-81.
12. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E25-30.
13. Kim KH, Ahn SH, Chung HY et al. Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J. Gastroenterol. Hepatol. 2004; 19: 847-53.
14. Marcellin P, Giostra E, Martinot-Peignoux M et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991; 100: 1432-4.
15. Blanpain C, Knoop C, Delforge ML et al. Reactivation of hepatitis B after transplantation in patients with preexisting anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation 1998; 66: 883-6.
16. Hino K, Basuni AA, Ireland J et al. Reappearance of hepatitis B surface antigen in immunocompromised individuals: reinfection or reactivation? Dig. Dis. Sci. 2002; 47: 415-18.
17. Grotz W, Rasenack J, Benzing T et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin. Nephrol. 1998; 49: 385-8.
18. Luvira U, Kanjanakul I, Kuvanont S. Prevalence of abnormal liver function and hepatitis B antigenemia in hepatitis B antibody positive kidney transplant patients. Transplant Proc. 2000; 32: 1937-8.
19. Larghi A, Leffler D, Frucht H et al. Hepatitis B virus reactivation after kidney transplantation and new onset lymphoma. J. Clin. Gastroenterol. 2003; 36: 276-80.
20. Lu M, Lorentz T. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis B virus despite the presence of protective anti-hepatitis B surface antibody. J. Infect. Dis. 2003; 187: 1323-6.
21. Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-4.
22. Krugman S, Overby LR, Mushahwar IK et al. Viral hepatitis, type B. studies on natural history and prevention reexamined. N. Engl. J. Med. 1979; 300: 101-6.
23. Perrillo RP, Chau KH, Overby LR et al. Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses. Gastroenterology 1983; 85: 163-7.
24. Lindsay KL, Nizze JA, Koretz R et al. Diagnostic usefulness of testing for anti-HBc IgM in acute hepatitis B. Hepatology 1986; 6: 1325-8.
25. Waters JA, Kennedy M, Voet P et al. Loss of the common 'A' determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J. Clin. Invest. 1992; 90: 2543-7.
26. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-9.
27. Terrault NA, Zhou S, McCory RW et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28: 555-61.